“Late” Withdrawal Syndrome after Carbamazepine In Utero Exposure in a CYP2C9 Slow Metabolizer Newborn

“Late” Withdrawal Syndrome after Carbamazepine In Utero Exposure in a CYP2C9 Slow Metabolizer Newborn

We report a case of carbamazepine withdrawal syndrome following in utero exposure to carbamazepine related to a pharmacogenetic predisposition factor. The infant was born at 37 1/7 weeks’ gestation by cesarean section to a mother treated for epilepsy with carbamazepine. One hour and thirty minutes a...

Full description

Bibliographic Details
Main Authors: Caroline F. Samer, Evangelia Passia, Nathalie Rock, Riccardo E. Pfister, Kuntheavy R. Ing Lorenzini, Jules Desmeules
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-04-01
Series:Frontiers in Pharmacology
Subjects:
carbamazepine
drug withdrawal
pharmacogenetics
cytochrome P450
epilepsy
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2017.00217/full

Similar Items

Similar Items